AI across the RNA therapeutics lifecycle: discovery, development, and the road to personalized medicine
Year: 2026
Type: article
Abstract: Jokūbas Leikauskas, Editor, Nucleic Acid Insights, speaks with Edward Miracco, Head of Enterprise AI Enablement, Moderna, about enterprise AI adoption, AI-driven lipid nanoparticle and neoantigen design, rare disease applications of mRNA, and the future of RNA therapeutics.
Source: Nucleic Acid Insights
Author: Edward Miracco
Institution: Moderna Therapeutics (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W7226025882
